Novartis Drug Shows Success With Plaque Psorasis

It was three times as effective as a placebo in testing

By Christopher Freeburn, InvestorPlace Writer

Novartis (NYSE:NVS) announced on Thursday that mid-stage drug trails of its new psoriasis treatment had proven effective.

The Swiss drug maker said that its new drug, AIN457 mitigated moderate-to-severe symptoms in people suffering from plaque psoriasis nearly three times as much as people in a control group taking a placebo.

Novartis Drug Shows Promise in Heart Failure
Novartis Drug Shows Promise in Heart Failure

Plaque psoriasis inflicts about 2% of the population. The condition causes scaling, pain, itching and redness on hands and feet.

The drug maker is scheduled to present detailed finding from its study later today at a medical event in the Czech Republic.

Shares of Novartis rose about 1% in Thursday mid-day trading in New York.

In July, the company won U.S. Food and Drug Administration approval for its anti-breast cancer treatment, Affinitor. The drug, which blocks proteins needed by cancer cells to reproduce, was derived from bacteria harvested from the soils of Easter Island.

Article printed from InvestorPlace Media,

©2018 InvestorPlace Media, LLC